Ramipril Capsule
Product Images NDC 50090-3873

4 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 50090-3873). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Ramipril Str)

FDA Label Image

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)
A line graph depicting the proportion of patients over days of follow-up comparing Ramipril treatment versus placebo. The graph shows two lines: a solid line for Ramipril and a dashed line for placebo, with the proportion of patients increasing over time, and a p-value of 0.0001 indicated, suggesting statistical analysis of the difference between the two groups.*
FDA Label Image

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)
A forest plot showing relative risk of a composite outcome in the Ramipril group compared to placebo across various patient subgroups (such as cardiovascular disease, diabetes, age, sex, hypertension, coronary artery disease history, myocardial infarction history, cerebrovascular disease, peripheral vascular disease, and microalbuminuria). The chart includes number of patients and incidence rates in the placebo group, with confidence intervals for relative risk indicated by horizontal lines and markers on a logarithmic scale axis.*
FDA Label Image

Label Image (Lbl500903873)

Label Image (Lbl500903873)
The label for Ramipril 2.5 mg capsules from A-S Medication Solutions. The label includes the product NDC 50090-3873-0, dosage strength of 2.5 mg, and states the product contains 100 capsules. Storage instructions advise keeping at 68 to 77 degrees Fahrenheit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.